Shingles: What s New to Know
|
|
- Adam Morton
- 5 years ago
- Views:
Transcription
1 This material was prepared by the New England Quality Innovation Network-Quality Improvement Organization (NE QIN-QIO), the Medicare Quality Improvement Organization for New England, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy. CMSRIF Shingles: What s New to Know Vaccine Recommendations 2018 July 24, 2018 Stefan Gravenstein, MD, MPH If you haven t already, please dial in to the audio line: Passcode: Slides may be downloaded at:
2 Conflict of Interest Statement Stefan Gravenstein, MD, MPH serves as a consultant to Merck & Co. 2
3 Learning Objectives Identify what Shingles is, who gets it and why we should care Apply ACIP Recommendations for Shingles prevention - Using data to support recommendations - Vaccine storage requirements, durability and side effects Evaluate treatment choices for Shingles 3
4 Polling Question If an administration error occurs when vaccinating an individual you should immediately report it to: Vaccine Adverse Event Reporting System (VAERS) Vaccine Error Reporting Program (VERP) Both
5 Polling Question Local or systemic side effects for Zostavax and Shingrix: Have the same or similar impact on the individual Zostavax side effects can be more impactful Shingrix side effects can be more impactful
6 What is Shingles? (aka Herpes Zoster) Shingles is caused by Varicella Zoster Virus (VZV) Primary infection with VZV causes highly contagious Chicken Pox Reactivation causes Shingles VZV can reactivate later in a person s life and cause Shingles or Herpes Zoster Shingles rash Chicken Pox rash 6
7 Symptoms First: localized pain- burning, throbbing or stabbing Before rash appears days to weeks later Then, rash: painful maculopapular vesicular Along nerve pathways Typically, unilateral: face or trunk Vesicles dry and heal in 2-4 weeks Fever Headache Photophobia Nausea Source: CDC/John Noble, Jr., M.D. 7
8 Complications Postherpetic Neuralgia (PHN) Risk factors include Age 50 Severe pain at any time It can begin before or after onset of rash Extensive rash Trigeminal or ophthalmic distribution of rash Herpes Zoster Ophthalmicus ~15% of HZ cases Involves ophthalmic division of trigeminal nerve Untreated 50-70% acute ocular complications Can chronic ocular complications, blindness CDC. Prevention of Herpes Zoster. MMWR (RR-5): p
9 Complications Neurologic complications Myelitis Encephalitis, Meningoencephalitis, Ventriculitis Cranial nerve palsies Ischemic stroke syndrome VZV viremia Cutaneous dissemination (bilateral) Pneumonia, hepatitis Disseminated intravascular coagulation Dermatologic complications Secondary rash infections Permanent scarring and changes in pigmentation CDC. Prevention of Herpes Zoster. MMWR (RR-5): p
10 Complications: PHN Pain 30 days: in 18-30% of zoster cases Mild to excruciating pain after rash cleared Constant, intermittent, or with trivial stimuli May persist weeks, months or even years Can cause Sleep, mood, work disruption Activities of daily living impairment Social withdrawal and depression CDC. Prevention of Herpes Zoster. MMWR (RR-5): p
11 Who gets Shingles? Risk factors: Past Chicken Pox or varicella vaccination USA- >99% adults >40 yo s/p Chicken pox A person s risk for herpes zoster may increase as their immunity declines r/t : Age Medical Conditions (e.g., cancer, stress, HIV) Medications (e.g., chemo/radiotherapy, steroids) 11
12 Who is most at risk? People with compromised or suppressed immune systems including those: With cancer With Human Immunodeficiency Virus (HIV) After bone marrow or solid organ transplantation Who are taking immunosuppressive medications Steroids Chemotherapy Transplant and connective tissue disease-related immunosuppressive medications 12
13 Why should we care? ~1 million cases annually 1,2 ~1 /3 of us will eventually get HZ (absent vaccine) Age increases incidence, ranging from: <1 case/1000 children to >15 cases/1000 population 80 years and older 2,3, % of adults will go on to develop PHN Risk for PHN also increases with HZ risks 1. Jumaan et al., JID, 2005, 191:2002-7, 2. Yawn, et al., Mayo Clin Proc. 2007; 82:1341-9, 3. Insinga et al., J Gen Intern Med. 2005, 20: Harpaz et al, IDWeek 2015, 5. CDC, provisional unpublished data from NHIS 13
14 Vaccine Options 14
15 Zostavax (ZVL) ZVL (Zostavax) A live attenuated virus vaccine Single sub-cutaneous (SQ) dose
16 Shingrix (RZV) RZV (Shingrix) Recombinant zoster vaccine 2-dose intramuscular (IM) series 2 nd dose 2-6 months after the first 16
17 Polling Question Storage requirements for Shingrix requires the vaccine to be kept? In a Refrigerator In a Freezer At room temperature 17
18 Route of Administration ZVL (Zostavax) Subcutaneous (SQ) 0.65ml / dose. Administer immediately after reconstitution to minimize loss of potency Unused vaccine should be discarded if not used within 30 minutes RZV (Shingrix) Intramuscular (IM) 0.5ml /dose Shingrix Administer immediately after reconstitution or store in the refrigerator for up to 6 hours 2 dose series, spaced 2 to 6 months apart Source: CDC website (accessed Feb 5, 2018); Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines ; Refer to product package inserts for further. 18
19 ZVL (Zostavax) Storage: Freezer (between -58 and +5 F) for powder containing vial Diluent stored at room temperature (between 68 and 77 F) or refrigerator (between 36 and 46 F) Do not freeze diluent Protect vials from light Vaccine: Storage and Durablility RZV (Shingrix) Storage: Refrigerator (between 36 and 46 F) Store both vials together in refrigerator before reconstitution protect vials from light DO NOT FREEZE Discard if vaccine has been frozen Source: CDC website (accessed Feb 5, 2018); Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines ; Refer to product package inserts for further. 19
20 Side Effects ZVL (Zostavax) Injection site reactions In rare instances Disseminated rash Herpes Zoster in immunocompetent recipients Life threatening and fatal complications in immune compromised recipients RZV (Shingrix) A sore arm with mild or moderate pain Redness and swelling at site of injection ~1 out of 6 experience Grade 3 side effects preventing them doing regular activities. Symptoms resolve on their own in about 2-3 days Side effects were more common in younger people Patients might have a reaction to either or both doses Source: CDC website (accessed Feb 5, 2018); Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines ; Refer to product package inserts for further. 20
21 Notes from the Field: May 25, 2018 Vaccine Administration Errors Involving Recombinant Zoster Vaccine United States, There were 155 reports to the VAERS system, of which 13 (8%) documented vaccine administration errors. In addition, CDC has received calls about Shingrix administration errors or how to avoid them. 21
22 Highlights/Lessons Learned Storage and administration requirements differ between vaccines It takes time to adjust to new vaccine techniques and procedures Counsel patients about the potential impact of vaccination on their regular routine. Report any adverse events via VAERS* and administration errors via VERP** *VAERS: Vaccine adverse event reporting system ( **VERP: Vaccine error reporting program ( 22
23 Advisory Committee on Immunization Practices (ACIP) Recommendations
24 1) RZV is recommended for the prevention of HZ and its complications for immunocompetent adults aged 50 y Benefits HZ efficacy >90%: 97% (50-69 yo) and 91% (70+ yo) High efficacy against PHN (50+ yo) Durable efficacy >85% for 4 years post-vaccination Harms ACIP: Recombinant zoster vaccine (RZV) SAEs ~ between vaccinated and comparison groups But: Grade 3 reactions in 17% vs 3% placebo 24
25 RZV Grade 3 events Grade 3 Reactions severe enough to prevent normal activities Grade 3 injection-site reactions Pain, redness, swelling 9.4% RZV vs 0.3% placebo recipients Solicited systemic events (myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms) 10.8% RZV vs 2.4% placebo Similar proportion local grade 3 between 1 st and 2 nd dose More systemic grade 3 after 2 nd dose Most common solicited adverse reactions (grade 1 3) were pain (78%), myalgia (45%), and fatigue (45%) Lal H, et al. ; ZOE-50 Study Group. N Engl J Med 2015;372: Cunningham AL, et al. ; ZOE-70 Study Group. N Engl J Med 2016;375: ACIP GRADE RZV and ZVL;
26 2) RZV is recommended for prevention of HZ and its complications for immunocompetent adults who previously got live zoster vaccine (ZVL) Efficacy RZV (Shingrix) is more efficacious than ZVL (Zostavax) in first year all ages >50 years old: >97% RZV vs 69% ZVL; Differences are larger at older ages RZV maintained > 85% during the first 4 years for all ages Studies indicate significant waning of protection from ZVL: Vaccine Effectiveness (VE) drops 15-25% in first year By 6 years post vaccination, VE is < 35% Negligible protection by 10 years ACIP: Recombinant zoster vaccine (RZV) 26
27 3) RZV is preferred over ZVL for the prevention of HZ and complications *These vaccines have not been studied head to head efficacy trial Efficacy RZV efficacy estimates are significantly higher than ZVL estimates across all ages years 97% vs 64% years 91% vs 41% >80 years 91% vs 18% HZ/su appears to wane at a slower rate than ZVL over the first 4 years Expected cases of HZ and PHN averted are far greater with HZ/su compared to ZVL Adverse effects Neither vaccine is associated with SAEs in immunocompetent persons RZV is more reactogenic than ZVL Economics ACIP: Recombinant zoster vaccine (RZV) RZV leads to less disease and reduced costs (vaccine + expected disease costs) 27
28 Data Supporting Recommendations 28
29 Data Supporting Recommendations 29
30 Polling Question If an administration error occurs when vaccinating an individual you should immediately report it to: Vaccine Adverse Event Reporting System (VAERS) Vaccine Error Reporting Program (VERP) Both
31 Polling Question Local or systemic side effects for Zostavax and Shingrix: Have the same or similar impact on the individual Zostavax side effects can be more impactful Shingrix side effects can be more impactful
32 Summary Two shingles vaccines: one killed, one live. A new option for immunocompromised patients who cannot take a live vaccine RZV received preferred recommendation from ACIP Best Practice- Integrate specific training into your practice on the new Shingrix vaccine (storage and AEs) Make a firm yet positive vaccine recommendation Advanced discussion of side effects can help prepare patients in the event they occur 32
33 Resources 33
34 34
35 Connect with the New England QIN-QIO on Social Media! 35
36 The Learning Center Captures valuable data such as: Pre and post tests Knowledge checks Surveys Learners course specific reports: Test responses Activity completions Feedback Number of Attempts Access at Learning4Quality.org Questions, comments, or concerns, 36
37 Contact Us Russ Cooney Program Coordinator New England QIN-QIO
9/12/2018. Zoster. Herpes Zoster (Shingles) Complications of Herpes Zoster
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Zoster September 2018 Chapter 22 Photographs and images included in this presentation are licensed solely
More informationInfluenza, Pneumococcal and Herpes Zoster Vaccination
Influenza, Pneumococcal and Herpes Zoster Vaccination Chris Campanile, MD, Ph.D Clinical Consultant, Healthcentric Advisors Clinical Associate Professor of Family Medicine, Brown University Alpert Medical
More informationDisclosures. I have no financial interests in immunizations discussed here. I may discuss off-label use of licensed vaccines
2/28/18 Disclosures I have no financial interests in immunizations discussed here I may discuss off-label use of licensed vaccines Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) epidemiology, United
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationHERPES ZOSTER This resource is designed to offer pharmacists a concise and accurate tool to support assessing,
PHARMACISTS HELPING PROTECT PATIENTS FOCUS ON HERPES ZOSTER This resource is designed to offer pharmacists a concise and accurate tool to support assessing, recommending, and administering vaccines to
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationWhat You Should Know about the 2018 Adult Immunization Schedule & New Recommendations
What You Should Know about the 2018 Adult Immunization Schedule & New Recommendations Adult Immunization Conference April 10, 2018 Susan M. Lett, M.D., MPH Medical Director Immunization Program Massachusetts
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE Revisions as of /4/10 Zostavax should not be given concomitantly with Pneumovax 3 due to reduced immune response to Zostavax.
More informationWhat You Should Know about the 2018 Immunization Schedule & New Recommendations
What You Should Know about the 2018 Immunization Schedule & New Recommendations AAP Webinar April 19, 2018 Susan M. Lett, M.D., MPH Medical Director Immunization Program Massachusetts Department of Public
More informationNew Herpes Zoster Vaccine Shingrix Expected to Become Available for Vaccines for Adults (VFA) Sites in July 2018
June 25, 2018 New Herpes Zoster Vaccine Shingrix Expected to Become Available for Vaccines for Adults (VFA) Sites in July 2018 Vaccine pre-release guidance for VFA program enrolled sites Background On
More informationProf Dr Najlaa Fawzi
1 Prof Dr Najlaa Fawzi is an acute highly infectious disease, characterized by vesicular rash, mild fever and mild constitutional symptoms. is a local manifestation of reactivation of latent varicella
More informationEmerging Issues in Reactivated Herpes Zoster Disease
Emerging Issues in Reactivated Herpes Zoster Disease Tim Hilderman, MD FRCPC 2018 Infection Prevention and Control Across the Continuum Friday, June 22 nd, 2018 DISCLOSURE STATEMENT Type of relationship
More informationTo provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More informationZostavax vaccine: now fully subsidised
Dermatology Infections Older person s health Virology Zostavax vaccine: now fully subsidised Zostavax is a herpes zoster (shingles) vaccine that will become fully subsidised from 1 April, 2018 for people
More informationShingrix (zoster vaccine recombinant, adjuvanted) NEW PRODUCT SLIDESHOW
Shingrix (zoster vaccine recombinant, adjuvanted) NEW PRODUCT SLIDESHOW Introduction Brand name: Shingrix Generic name: Zoster vaccine recombinant, adjuvanted Pharmacological class: Shingles vaccine Strength
More informationBackground Rationale for resource
Slide 1 Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering
More informationHERPES ZOSTER VACCINATION
HERPES ZOSTER VACCINATION Herpes Zoster (shingles) is a reactivation of the varicella zoster infection in some-one who has previously had varicella(chicken pox) disease Painful, unilateral, self-limiting
More informationWelcome to the CIC Education Hour
Welcome to the CIC Education Hour Shingles Vaccine 2.0: What you need to know Objectives Explain the clinical benefits and recommendations for administration of Shingrix, the new shingles vaccine Explain
More informationZOSTAVAX Zoster Vaccine Live Lyophilized preparation for subcutaneous injection
9815603 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZOSTAVAX 1 safely and effectively. See full prescribing information for ZOSTAVAX. ZOSTAVAX
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Update on Adult Immunization Strategies: Understanding the Current Recommendations EDWARD A. DOMINGUEZ, MD, FACP, FIDSA Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical Center,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Registration No.: 1C 10/54 (NBC) Importer / Manufacturer: MSD (Thailand) Ltd. / Merck Sharp & Dohme Corp., West Point, Pennsylvania 19486, USA SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL
More informationVaricella (Chickenpox) and Varicella Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Varicella (Chickenpox) and Varicella Vaccines September 2018 Photographs and images included in this
More informationApproximately 25% of people develop shingles during their lifetime, with the majority of cases occurring in those over 50 years of age.
ÜNZÜLE ALPASLAN WHAT IS SHINGLES? Shingles is an infection of an individual nerve and the skin surface that is supplied by the nerve; it is caused by the varicella-zoster virus - the same virus that causes
More informationBackground Rationale for resource
Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering a
More informationShingles. A Guide to Understanding Herpes Zoster. By Sarah Weis, PharmD Candidate 2012
Shingles A Guide to Understanding Herpes Zoster Information Every Elder Should Know By Sarah Weis, PharmD Candidate 2012 Herpes zoster, also known as shingles, effects up to 1 million people every year
More informationOverview of Immunizations for People Who Work in Labs
Overview of Immunizations for People Who Work in Labs CLMA/ASCLMS Spring Meeting Little Rock, AR April 5, 2019 Jennifer Dillaha, MD Medical Director, Immunizations Medical Advisor, Health Literacy Arkansas
More informationLes 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies
Les 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies VZV Epidemiology and Pathogenesis 98% adults Respiratory spread 1,000,000/year and increasing CMI continuously boosted
More informationQuality ID #474: Zoster (Shingles) Vaccination National Quality Strategy Domain: Community/Population Health Meaningful Measure Area: Preventive Care
Quality ID #474: Zoster (Shingles) Vaccination National Quality Strategy Domain: Community/Population Health Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES
More informationHot off the press, What s new for immunizations in 2017?
Hot off the press, What s new for immunizations in 2017? Jennifer Girotto, PharmD, BCPPS Faculty Disclosure Dr. Girotto has no actual or potential conflicts of interest associated with this presentation.
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SHINGRIX safely and effectively. See full prescribing information for SHINGRIX. SHINGRIX (Zoster
More informationWhat s New With Immunizations
What s New With Immunizations 2018 Annual Update COURTNEY A. ROBERTSON, PHARMD, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF LOUISIANA AT MONROE COLLEGE OF PHARMACY Disclosures No financial disclosures
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01B adjuvanted) Suspension for Injection Read this
More informationA Call To Arms: The Basics for Select Vaccines
Page 1 A Call To Arms: The Basics for Select Vaccines A Call To Arms: The Basics for Select Vaccines Wendy Rosenthal, Pharm.D. A Call To Arms: The Basics for Select Vaccines Vaccine Science Basics of Immunity
More informationHot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC
Hot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC Infectious Diseases Consultant Island Health Authority Clinical Assistant Prof of Med, UBC Victoria Faculty/Presenter Disclosure Wayne
More informationIMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine
IMMUNIZATION PROTOCOLS FOR PHARMACISTS VARICELLA Live Virus Vaccine I. ORDER: 1. Screen for contraindications and evidence of immunity (Section VII.K.) 2. Provide a current Vaccine Information Statement
More informationAged 70 or 78? There s now a vaccine to help protect you against shingles
Aged 70 or 78? There s now a vaccine to help protect you against shingles This leaflet describes shingles and the benefits of the vaccination. The new shingles vaccine is being phased in over the next
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More informationShingles: Good Practice Guide. Advice and guidance on how to improve shingles vaccination uptake
Shingles: Good Practice Guide Advice and guidance on how to improve shingles vaccination uptake Shingles Shingles, also known as herpes zoster, is caused by the reactivation of a latent varicella zoster
More informationImmunization Update: Shingles, Mumps and Best Practice Oh my!!!
Immunization Update: Shingles, Mumps and Best Practice Oh my!!! Kevin W. Cleveland, PharmD, ANP Assistant Dean and Associate Professor Idaho State University College of Pharmacy February 2018 Disclosure
More informationImmunization Update 2018
Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts
More informationPackage Leaflet: Information for the user
Package Leaflet: Information for the user ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live) Read all of this leaflet carefully before
More informationAged 70 or 78? There s a vaccine to help protect you from the pain of shingles
Aged 70 or 78? There s a vaccine to help protect you from the pain of shingles This leaflet describes shingles and the benefits of the vaccination and who is eligible for the vaccine this year. There is
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More informationZoster Vaccine for Older Adults
BC Centre for Disease Control IMMUNIZATION FORUM 29 Zoster Vaccine for Older Adults Michael N. Oxman, M.D. Professor of Medicine and Pathology University of California, San Diego VASDHS Staff Physician
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (Zoster Vaccine Live) Suspension for
More informationUpdate on Immunizations H. Keipp Talbot, M.D., M.P.H.
Update on Immunizations H. Keipp Talbot, M.D., M.P.H. Vanderbilt University Medical Center 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding from Sanofi
More informationIn Case of Technical Difficulties
Shingles Vaccines: What You Need to Know Wednesday, December 6, 2017 12:00 PM ET In Case of Technical Difficulties If you hear an echo: Make sure you are only logged in once on your computer Select one
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE
Kenneth McCall, BSPharm, PharmD Associate Professor UNE Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize each of the CDC recommended flu vaccines
More informationDeclarations. Herpes Zoster: The disease and the vaccines. Zoster: Latency and Reactivation. Take home message. Risk factors for Herpes Zoster
Herpes Zoster: The disease and the vaccines Tony Cunningham Centre for Virus Research The Westmead Institute for Medical Research Sydney, Australia Declarations Chair, Publications committee, GSK Shingrix
More informationIncreasing Zostavax Awareness and Uptake at Optimus Health Care. Background of Need
1 SEARCH Project Abstract Student: Colleen Linari, RN Preceptor: Luis Rojas, APRN July 2012 Increasing Zostavax Awareness and Uptake at Optimus Health Care Background of Need Herpes zoster (HZ) or shingles
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Sunday CME Breakfast Update on Adult Immunization Strategies: Understanding the Current Recommendations Edward Dominguez, MD Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE Update as of 06 2010 Addition of IXIARO, Inactivated, Adsorbed vaccine; grown in tissue culture
More informationVaccination to protect against shingles
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2018 and contraindications and precautions Revised July 2018 NES and HPS accept
More informationSection 10.5 Varicella
Section 10.5 Varicella Chickenpox Introduction Transmission Signs and Symptoms Complications Diagnosis Treatment Infection Prevention and Control Precautions for Residents with Chickenpox Additional considerations
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (Zoster Vaccine Live) Suspension for
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More informationThere s a vaccine to help. protect you from the pain of. shingles. the safest way to protect your health
There s a vaccine to help protect you from the pain of shingles the safest way to protect your health There is a vaccine that helps reduce your risk of getting shingles and reduces the severity of symptoms
More informationOTE. Shingrix : A New Herpes Zoster Subunit Vaccine. Shingrix : A New Herpes Zoster Subunit Vaccine
HAR Vol. 33, Issue 7 April 2018 M A N OTE Established 1985 Shingrix : A New Herpes Zoster Subunit Vaccine Amy Kernick, harmd Candidate in this issue Shingrix : A New Herpes Zoster Subunit Vaccine ersonalized
More informationImmunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist
Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix
More information11/17/2013 THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS. Pneumococcal Vaccines for Adults (PPV) Pneumococcal Vaccines
THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS CAROL A. KAUFFMAN, MD VA ANN ARBOR HEALTHCARE SYSTEM UNIVERSITY OF MICHIGAN Will discuss: bacterial vaccines made of toxoids or polysaccharide capsular
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationImmunizations: new and sometimes confusing recommendations MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE AND RADY CHILDREN S HOSPITAL SAN DIEGO
Immunizations: new and sometimes confusing recommendations MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE AND RADY CHILDREN S HOSPITAL SAN DIEGO Disclosures I have no financial disclosures related to this
More informationImmunizations for Health Care Workers
Immunizations for Health Care Workers Tanisha Taylor, MD, MPH Senior Medical Director Barnabas Health Corporate Care Tanisha Taylor MD, MPH Senior Medical Director Barnabas Health Corporate Care CDC Immunizations
More informationSystematic Review Report: Efficacy and safety of adjuvanted herpes zoster subunit vaccine. Drug Assessment Working Group October 2018
Systematic Review Report: Efficacy and safety of adjuvanted herpes zoster subunit vaccine Drug Assessment Working Group October 2018 Table of Contents Page number Abbreviations/Glossary 3 Executive summary
More informationUpdate on Immunizations and the Shingles Vaccine
Update on Immunizations and the Shingles Vaccine Conflict of Interest Disclosure I have no conflicts of interest to disclose. Sarah Scoular, PharmD., BCPS Annual Meeting 2018 Objectives 1. Describe the
More informationThere s now a vaccine to help protect you against. shingles. the safest way to protect your health
There s now a vaccine to help protect you against shingles the safest way to protect your health There is now a vaccine that helps reduce your risk of getting shingles and reduces the severity of symptoms
More informationPatient Immunization FAQ Sheet
Patient Immunization FAQ Sheet Shingles Vaccine: Q: Who should get the shingles vaccine (Zostavax )? A: Anyone 60 years of age or should get the shingles (herpes zoster) vaccine. There is no maximum age
More informationHerpes zoster: The disease and the vaccines Tony Cunningham Centre for Virus Research The Westmead Institute for Medical Research Sydney, Australia
Herpes zoster: The disease and the vaccines Tony Cunningham Centre for Virus Research The Westmead Institute for Medical Research Sydney, Australia Declarations Chair, Publications committee, GSK Shingrix
More informationDilemmas in Zoster Eye Disease Stephanie Klemencic, OD, FAAO
Dilemmas in Zoster Eye Disease Stephanie Klemencic, OD, FAAO Please silence all mobile devices and remove items from chairs so others can sit. Unauthorized recording of this session is prohibited. Disclosure
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Amar PP,, 2014; Volume 3(3): 123-127 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE A REVIEW ON HERPES ZOSTER AMAR PP 1, AJINKYA C 2, TOHID NB 2, ROHIDAS P 2, AVINASH C 2 1. Assistant
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationIn Case of Technical Difficulties
Updates from October 2017 ACIP Meeting Thursday, November 9, 2017 12:00 PM ET In Case of Technical Difficulties If you hear an echo: Make sure you are only logged in once on your computer Select one form
More informationAntigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Herpes zoster
Antigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Herpes zoster Prepared as part of a Ministry of Health contract for services by the Immunisation Advisory Centre Department
More informationZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck), Refrigerator Stable.
ZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck), Refrigerator Stable. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ZOSTAVAX. It does not contain
More informationImmunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H.
Immunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H. Vanderbilt University School of Medicine 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding
More informationHerpes zoster. Diagnosis, Complications, Treatment, Prevention 서울대학교병원 FM R2 임하연
Herpes zoster Diagnosis, Complications, Treatment, Prevention 2018.04.14 서울대학교병원 FM R2 임하연 1 2 Overview reactivation of lat ent VZV along sensory nerve VZV(varicella-zoster virus) Human herpes virus-3
More informationCondition: Herpes Zoster Ophthalmicus (HZO)
Condition: Herpes Zoster Ophthalmicus (HZO) Description: Herpes zoster represents a reactivation of the varicella zoster virus (VZV) which leads to characteristic skin lesions and, in many cases, ocular
More informationShingles (herpes zoster) vaccine programme in Scotland for 2016/17
Annual report Shingles (herpes zoster) vaccine programme in Scotland for 216/17 Executive summary Shingles vaccine coverage for Scotland in the fourth year of the programme is presented in this report.
More informationShingles vaccination for those aged 70 to 79
Shingles vaccination for those aged 70 to 79 Shingles affects a lot of people as they get older. It often causes severe pain which can last for months or sometimes years. Shingles is more common and more
More informationZOSTAVAX is indicated for immunisation of individuals 50 years of age or older.
1 PRODUCT NAME ZOSTAVAX Zoster Vaccine Live (Oka/Merck) Refrigerator stable 2 QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution with accompanying vial or pre-filled syringe of diluent, 1 dose
More informationThe introduction of a vaccine for people aged 70 years (routine cohort) and 79 years (catch up cohort) to protect against shingles
The introduction of a vaccine for people aged 70 years (routine cohort) and 79 years (catch up cohort) to protect against shingles An update for registered healthcare professionals December 2013 Quality
More informationAged 70 or 79? There is now a vaccine to help protect you against shingles
Aged 70 or 79? There is now a vaccine to help protect you against shingles Shingles affects a lot of people as they get older. It often causes severe pain which can last for months or sometimes years.
More informationWendy Rosenthal, Pharm.D.
Wendy Rosenthal, Pharm.D. This program has been supported by an educational grant from Merck Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of
More informationImmunization Update 2017
Immunization Update 2017 Tamara Sheffield, MD, MPA, MPH November 10, 2017 DISCLOSURE: I have no conflicts of interest to disclose I will be discussing off label use I will be discussing an unlicensed vaccine
More informationHerpes zoster vaccine in Korea
Review article CLINICAL EXPERIMENTAL VACCINE RESEARCH Herpes zoster vaccine in Korea Clin Exp Vaccine Res 2013;2:92-96 pissn 2287-3651 eissn 2287-366X Won Suk Choi Division of Infectious Diseases, Department
More informationAlphaherpesvirinae. Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV)
Alphaherpesvirinae Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV) HERPES SIMPLEX VIRUS First human herpesvirus discovered (1922) Two serotypes recognised HSV-1 & HSV-2 (1962) HSV polymorphism
More informationzoster vaccine; re-vaccination; adjuvant; glycoprotein E; influenza vaccine.
The Journal of Infectious Diseases EDITORIAL COMMENTARY Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration
More informationAcyclovir dose for chicken pox
Buscar... Acyclovir dose for chicken pox Acyclovir (Zovirax) treats infections caused by the herpes viruses including genital herpes, cold sores, shingles and chicken pox. Includes Acyclovir side effects.
More informationShingles vaccination for those aged 70 to 79
Shingles vaccination for those aged 70 to 79 Shingles affects a lot of people as they get older. It often causes severe pain which can last for months or sometimes years. Shingles is more common and more
More informationAntiviral treatment for shingles and its complications in immunocompetent adults
Quality Improvement Scotland In response to an enquiry from NHS Greater Glasgow & Clyde Number 21 January 2008 Antiviral treatment for shingles and its complications in immunocompetent adults Description
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SHINGRIX. Herpes Zoster vaccine (non-live recombinant, AS01 B adjuvanted)
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01 B adjuvanted) Suspension for injection Active immunizing agent GlaxoSmithKline Inc.
More informationAssociation of Physical Trauma With Risk of Herpes Zoster Among Medicare Beneficiaries in the United States
BRIEF REPORT Association of Physical Trauma With Risk of Herpes Zoster Among Medicare Beneficiaries in the United States John X. Zhang, Riduan M. Joesoef, Stephanie Bialek, Chengbin Wang, and Rafael Harpaz
More informationBackground paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany
Bekanntmachungen Amtliche Mitteilungen Bundesgesundheitsbl 2017 60:1162 1179 DOI 10.1007/s00103-017-2618-6 Online publiziert: 7. September 2017 Springer-Verlag GmbH Deutschland 2017 Siedler A. 1 Koch J.
More informationAtlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique
Atlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique Reviewed and approved by specialists at the IWK Health Centre, Halifax,
More information6/29/2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018
Disclosure Statement New Drugs I have no conflicts of interest to disclose Steven Walden, PharmD, MPH WellCare Health Plans Manager, Clinical Implementations Learning Objectives At the completion of this
More informationZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable
PRODUCT INFORMATION ZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable DESCRIPTION ZOSTAVAX is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella - zoster virus
More informationGeneral Recommendations. General Best Practice Guidelines 9/10/2018. General Best Practice Guidelines for Immunization Part 1
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases General Best Practice Guidelines for Immunization Part 1 Chapter 2 September 2018 Photographs and images
More information